How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comComparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma
Description:
The goals of the NEUROBLASTOTEP trial is to compare the diagnostics performance of a the 18F-metafluorobenzylguanidine (18F-MFBG) Positron Emission Tomography / Computed Tomography scan (PET/CT) compared to 123I-metaiodobenzylguanidine (123I-MIBG scintigraphy (current gold standard) for imaging in neuroblastoma.
Sponsor:
Institut Curie
Contacts:
Carole Cagnotcarole.cagnot@curie.fr
+33147111891
Government Study Link:
NCT07111117 - Click here to see study onClinicalTrials.gov
123I-MIBG
Isotope(s):
IODINE-123
Radioisotope: I-123
Theranostic Role: SPECT Imaging
T1/2 (Half-Life): 13.2 Hours
Decay Mode: BETA, GAMMA
Energy: Beta: 127 keV (14%), 154 keV (2%) Gamma: 539 keV (1%), 159 keV (83%), 27 keV (71%)
Range: N/A
Decay Daughters: Te123 (Stable)
Status: FDA Approvals: DATSCAN®(2011), ADREVIEW® (2008)
Target(s):
- NET
18F-MFBG
Isotope(s):
FLUORINE-18
Radioisotope: F-18
Theranostic Role: PET Imaging
T1/2 (Half-Life): 1.8 Hours
Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
Energy: Eβ+ 635 keV
Range: N/A
Decay Daughters: O18 (Stable)
Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
Target(s):
- NET
Share your feedback
Help us improve your experience